These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Phase I clinical trial of methylene dimethane sulfonate. Smith DB; Fox BW; Thatcher N; Steward WP; Scarffe JH; Wagstaff J; Vezin R; Crowther D Cancer Treat Rep; 1987 Sep; 71(9):817-20. PubMed ID: 3621213 [TBL] [Abstract][Full Text] [Related]
47. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557 [TBL] [Abstract][Full Text] [Related]
48. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470 [TBL] [Abstract][Full Text] [Related]
50. Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial. Alberts DS; Hilgers RD; Moon TE; Martimbeau PW; Rivkin S Cancer Treat Rep; 1979 Feb; 63(2):301-5. PubMed ID: 109200 [TBL] [Abstract][Full Text] [Related]
51. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Sørensen P; Høyer M; Jakobsen A; Malmström H; Havsteen H; Bertelsen K Gynecol Oncol; 2001 Apr; 81(1):58-62. PubMed ID: 11277650 [TBL] [Abstract][Full Text] [Related]
52. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711 [TBL] [Abstract][Full Text] [Related]
53. Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma. Edmonson JH; Decker DG; Malkasian GD; Webb MJ Cancer Treat Rep; 1981; 65(11-12):1127-9. PubMed ID: 7296557 [No Abstract] [Full Text] [Related]
54. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer. Brown TD; Ettinger DS; Donehower RC J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770 [TBL] [Abstract][Full Text] [Related]